Contineum Therapeutics Files 2024 10-K
Ticker: CTNM · Form: 10-K · Filed: Mar 6, 2025 · CIK: 1855175
| Field | Detail |
|---|---|
| Company | Contineum Therapeutics, Inc. (CTNM) |
| Form Type | 10-K |
| Filed Date | Mar 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals
TL;DR
Contineum Therapeutics 2024 10-K filed: $39.6M assets, $19.1M liabilities. Equity $20.5M.
AI Summary
Contineum Therapeutics, Inc. filed its 2024 10-K on March 6, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly Pipeline Therapeutics, Inc., is involved in the pharmaceutical preparations industry. Key financial figures for 2024 include total assets of $39.6 million and total liabilities of $19.1 million, resulting in total equity of $20.5 million.
Why It Matters
This filing provides investors with a comprehensive overview of Contineum Therapeutics' financial health and operational status for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Contineum Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- $39.6B — Total Assets (Represents the company's total resources as of December 31, 2024.)
- $19.1B — Total Liabilities (Indicates the company's total obligations as of December 31, 2024.)
- $20.5B — Total Equity (Reflects the net worth of the company after deducting liabilities from assets as of December 31, 2024.)
- 16,940,594 — Revenue (Represents the company's total revenue for the fiscal year 2024.)
- 15,906,236 — Net Income (Shows the company's profit for the fiscal year 2024.)
Key Players & Entities
- Contineum Therapeutics, Inc. (company) — Filer of the 10-K
- Pipeline Therapeutics, Inc. (company) — Former name of Contineum Therapeutics
- 2024-12-31 (date) — Fiscal year end
- 2025-03-06 (date) — Filing date
- $39,630,511 (dollar_amount) — Total assets for fiscal year 2024
- $19,125,377 (dollar_amount) — Total liabilities for fiscal year 2024
FAQ
What was Contineum Therapeutics' net income for the fiscal year ended December 31, 2024?
Contineum Therapeutics reported a net income of $15,906,236 for the fiscal year ended December 31, 2024.
What is the company's primary industry classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
When did Pipeline Therapeutics, Inc. change its name to Contineum Therapeutics, Inc.?
The name change from Pipeline Therapeutics, Inc. to Contineum Therapeutics, Inc. occurred on April 5, 2021.
What were the total assets of Contineum Therapeutics as of December 31, 2024?
As of December 31, 2024, Contineum Therapeutics had total assets of $39,630,511.
What is the company's business address?
The business address for Contineum Therapeutics is 3565 General Atomics Court, Suite 200, San Diego, CA 92121.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 6, 2025 regarding Contineum Therapeutics, Inc. (CTNM).